Clozapine in Hemiballismus: Report of two cases

Clinical Neuropharmacology

Volumn 20, Issue 2, 1997, Pages 171-174

  Stojanovic, Marina ^a   Sternic, Nadezda ^a   Kostic, Vladimir S ^a,b  

^a Institute of Neurology   (Yugoslavia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Clozapine; Hemiballism

Indexed keywords

CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; HALOPERIDOL;

AGED; ARTICLE; CASE REPORT; DOPAMINERGIC ACTIVITY; HEMIBALLISM; HUMAN; HYPERKINESIA; INVOLUNTARY MOVEMENT; MALE; PRIORITY JOURNAL; REMISSION; SUBTHALAMIC NUCLEUS;

EID: 0030987238     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199704000-00010     Document Type: Article

References (22)

1. Shannon KM. Hemiballismus. Clin Neuropharmacol 1990;13:413-25.
2. Dewey RB, Jankovic J. Hemiballism-hemichorea: clinical and pharmacological findings in 21 patients. Arch Neurol 1989;46:862-7.
3. Vidakovic A, Dragasevic N, Kostic VS. Hemiballism: report of 25 cases. J Neurol Neurosurg Psychiatry 1994;57:945-9.
4. Lang AE. Persistent hemiballism with lesions outside the subthalamic nucleus. Can J Neurol Sci 1985;12:125-8.
5. Bashir K, Manyam BV. Clozapine for the control of hemiballismus. Clin Neuropharmacol 1994;17:477-80.
6. Pfeiffer C, Wagner ML. Clozapine therapy for Parkinson's disease and other movement disorders. Am J Hosp Pharm 1994;51:3047-53.
7. Whittier JR. Ballism and the subthalamic nucleus (nucleus hypothalamicus; corpus Luysi). Arch Neurol Psychiatry 1947;58:672-92.
8. Penney JB, Young AB. Striatal inhomogeneities and basal ganglia functions. Mov Disord 1986;1:3-15.
9. Klawans HL, Weiner WJ. The pharmacology of choreatit movement disorder. In: Kerkut GA, Phillis LW, eds. Progress in neurobiology. Oxford, England: Pergamon Press, 1976;49-80.
10. Klawans HL, Moses H, Nausieda PA, Bergan D, Weiner WJ. Treatment and prognosis of hemiballismus N Engl J Med 1976;295:1348-50.
11. Kostic VS, Djuricic BM, Paschen W. Hemiballismus: changes in cerebrospinal fluid. Acta Neurol Scand 1988;78:115-7.
12. Polvsen UJ, Noring U, Fog R, et al. Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985;71:176-85.
13. Musser WS, Akil M. Clozapine as a treatment for psychosis in Parkinson's disease: a review. J Neuropsychiatry Clin Neurosci 1996;8:1-9.
14. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979;136:317-20.
15. Sajatovic M, Verbanac P, Ramirez LF, Meltzer HY. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. Neurology 1991;41:156.
16. Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A. Clozapine in Huntington's chorea. Neurology 1994;44:821-3.
17. Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987;48:263-7.
18. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-10.
19. Littrell K, Magill AM. The effect of clozapine on preexisting tardive dyskinesia. J Psychosoc Nurs Ment Health Serv 1993;31:14-8.
20. Bennett JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993;43:1551-5.
21. Boyce S, Rupniak NMJ, Steventon MJ. Iversen SD. Differential effects of D1 and D2 agonist in MPTP treated primates: functional implications for Parkinson's disease. Neurology 1990;40:927-33.
22. Gomez MB, Bedard PJ. Effects of D1 and D2 agonists and antagonists on dyskinesias produced by L-DOPA in 1-methyl, 4-phenyl, 1,2,3,6 tetrahydropyridine treated monkeys. J Pharmacol Exp Ther 1991;259:409-13.